See all news

WashU early AD initiative could yield broader clues


View News Article

If intervening ahead of symptoms in Alzheimer’s disease (AD) works in people with gene mutations that predispose them to getting sick at a younger age, then it will probably work in the rest of the population, principal investigator Randall Bateman theorized to BioWorld Today, and his team at Washington University (WashU) – testing drugs provided by big pharma – hopes to prove as much.

Categories: Uncategorized